CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

CalciMedica, Inc.

CalciMedica is developing therapeutics that inhibit CRAC channels to address life-threatening inflammatory diseases affecting the pancreas, kidney, and lung.

CalciMedica

CalciMedica | 1,134 followers on LinkedIn. Leader in the development of CRAC channel inhibitor drugs for inflammatory diseases | CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr.

Frederic Guerard

Founder and Managing Director at Danforth Advisors

Daniel Geffken

Chief Regulatory Officer CalciMedica

Raven Jaeger

SVP, Clinical Development at CalciMedica

Andrew Cunningham

We are delighted to welcome Stephen Bardin to the CalciMedica team as Chief Financial Officer, and look forward to working together as we continue to advance our clinical-stage pipeline. Read the press release: https://lnkd.in/excRjSrX

We are excited to be presenting the full data set from our Phase 2b CARPO trial of Auxora in #acutepancreatitis on a conference call and webcast, during which Prof. Robert Sutton will deliver his plenary presentation from the American College of Gastroenterology (ACG) Annual Scientific Meeting. See our press release for a description of the late-breaking, positive data, including a win ratio analysis, and for instructions to join the webcast: https://lnkd.in/eqDePnKK

We are pleased to announce a late-breaking abstract for a plenary presentation by Prof. Robert Sutton from the University of Liverpool at American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. Details in the press release: https://lnkd.in/egniHv87 #ACG2024

Earlier this week we shared the news that the first patient has been dosed in #KOURAGE , our Phase 2 trial evaluating Auxora for the treatment of severe acute kidney injury with associated acute hypoxemic respiratory failure (AHRF). There are currently no approved therapies for AKI and we look forward to continuing to evaluate Auxora as a potential treatment for this severe and underserved disease. See our press release: https://lnkd.in/e8HzWKjJ

Today we announced that the first patient has been dosed in #KOURAGE , our Phase 2 trial evaluating Auxora for the treatment of severe #acutekidneyinjury with associated acute hypoxemic respiratory failure (AHRF). We expect to share topline data from this trial in 2025. Read the press release: https://lnkd.in/eRmNxsik

We are excited to share that today we announced positive topline data from our Phase 2b CARPO trial of #Auxora in #acutepancreatitis (AP). The trial established a dose response for Auxora across multiple endpoints, identified both the target patient population and the likely drug dose for a pivotal trial, and re-affirmed Auxora’s safety profile and tolerability as seen in prior clinical trials. Read the press release: https://lnkd.in/gAgBCaAW

We recently completed enrollment in our ongoing Phase 2b clinical trial, CARPO, which is evaluating Auxora™ in patients with #acutepancreatitis with accompanying SIRS. For details on the clinical trial, visit https://lnkd.in/eTwrEFCa , or hear some of our study investigators discuss the potential for #Auxora to improve outcomes for patients with AP.

Today we announced that the last patient has been enrolled in our Phase 2b CARPO trial of Auxora™ in #acutepancreatitis (AP). Details here: https://lnkd.in/eqjarCww

Today CalciMedica reported financial results for the year ended December 31, 2023. Read the press release here: https://lnkd.in/eEFNhNSK

Yesteday we presented data from preclinical studies of Auxora in acute kidney injury at the 29th International AKI & CRRT Conference. The data show that Auxora hastens recovery of kidney function and improves survival in a rat model of #AKI . https://lnkd.in/g5h4vxbY

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	5.60M -	6.92M 23.63%	8.87M 28.14%	17.04M 92.15%	19.10M 12.09%
selling general and administrative expenses	5.60M -	6.92M 23.63%	8.87M 28.14%	17.04M 92.15%	19.10M 12.09%
research and development expenses	22.97M -	30.58M 33.12%	20.96M 31.45%	18.90M 9.82%	14.11M 25.34%
other expenses		72K -	2.16M 2,897.22%		2.96M -
cost and expenses	28.57M -	37.50M 31.26%	29.83M 20.45%	35.95M 20.50%	33.22M 7.59%
operating expenses	28.57M -	37.50M 31.26%	29.83M 20.45%	35.95M 20.50%	33.22M 7.59%
interest expense			143K -	126K 11.89%
ebitda	-28.39M -	-37.20M 31.01%	-29.83M 19.80%	-35.95M 20.50%	-29.92M 16.78%
operating income	-28.57M -	-37.50M 31.26%	-29.83M 20.45%	-35.95M 20.50%	-36.18M 0.65%
depreciation and amortization	175K -	303K 73.14%	395K 30.36%	519K 31.39%	338K 34.87%
total other income expenses net	192K -	72K 62.50%	2.16M 2,897.22%	-1.35M 162.65%	-2.96M 119.16%
income before tax	-28.38M -	-37.04M 30.51%	-27.53M 25.67%	-35.82M 30.11%	-35.60M 0.60%
income tax expense		-393K -	-538K 36.90%	-2.00M 271.19%	2.39M 219.58%
net income	-28.38M -	-37.04M 30.51%	-27.53M 25.67%	-35.82M 30.11%	-35.60M 0.60%
weighted average shs out	857.28K -	1.03M 20.51%	472.75K 54.24%	1.51M 220.31%	1.53M 1.37%
weighted average shs out dil	857.28K -	1.03M 20.51%	472.75K 54.24%	1.51M 220.31%	1.53M 1.37%
eps	-33.10 -	-35.85 8.31%	-58.24 62.45%	-23.66 59.38%	-23.20 1.94%	0 100%
epsdiluted	-33.10 -	-35.85 8.31%	-58.24 62.45%	-23.66 59.38%	-23.20 1.94%	0 100%

COM:CALCIMEDICA

CalciMedica

Last Close

3.45

22/11 21:00

Market Cap

49.23M

Beta: -

Volume Today

27.23K

Avg: -

Preview